Bimeda, a global leader in animal health solutions, today announced the U.S. launch ofGASTROBIM(omeprazole), thefirst and only FDA-approved bioequivalentto GastroGard(omeprazole) for the treatment and prevention of recurrence of gastric ulcers in horses and foals four weeks of age and older.Thisapple-flavoredformulationoffers veterinarians, trainers, and horse owners a clinically equivalent, high-quality alternative for the effective management of Equine Gastric Ulcer Syndrome (EGUS), addressing a critical need in equine health.Since itsinitiallaunch in 2024,GASTROBIMhas rapidlyemergedas the fastest-growing omeprazole product in Canada and Europe. Its strong adoption and positive reception among veterinarians and horse owners underscore its proven efficacy in treating and healing gastric ulcers, reinforcing its position as a trusted therapeuticoptionworldwide. The introduction ofGASTROBIMin the U.S. further expandsBimedasestablishedequine portfolio, which includes leading brands such asEquiMAX(1.87% ivermectin 14.03% praziquantel), Polyglycan(hyaluronic acid + chondroitin sulfates C4 & C6 + N-acetyl-D-glucosamine sterile solution),Detomequin(detomidine hydrochloride), andBimectin(ivermectin paste), and reflects the companys ongoing commitment to delivering innovative, reliable solutions to the equine industry.We are thrilled to introduceGASTROBIMto the U.S. market, said Eric Moore, DVM,Bimedas Head of Technical Services North America. Gastric ulcersremainone of the most common andperformance limitingconditions in horses. Offering a bioequivalent, rigorously tested treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price.Equine Gastric Ulcer Syndrome (EGUS) affects a significant percentage of performance horses, often leading to reduced appetite, behavioral changes, discomfort, and decreased athletic performance. By introducing a bioequivalent, apple-flavored alternative,Bimedaaims to broaden access to effective treatment options and support improved health and performance outcomes across the equine industry.